Pitot H C, Dragan Y, Sargent L, Xu Y H
McArdle Laboratory for Cancer Research, Medical School, University of Wisconsin, Madison 53706.
Environ Health Perspect. 1991 Jun;93:181-9. doi: 10.1289/ehp.9193181.
Specific biochemical changes occurring during hepatocarcinogenesis have been sought by many investigators. The development of multistage models for hepatocarcinogenesis in the rodent has renewed interest in such marker alterations in preneoplastic as well as neoplastic hepatocytes. Preneoplastic altered hepatic foci (AHF) exhibit specific histomorphologic changes as viewed with tinctorial stains and show a variety of biochemical changes as evidenced by enzyme and immunohistochemistry and by other histochemical markers. During the reversible stage of promotion when AHF are scored by multiple markers, the distribution of markers within these lesions differs with the use of different promoting agents. One interpretation of this finding is that each promoting agent stimulates the replication of a set of initiated cells exhibiting the phenotypic characteristics of a specific programmed phenotype. The same markers score AHF during the stage of progression, but many AHF in this stage are phenotypically heterogeneous, exhibiting in tissue sections a "focus-in-focus" pattern of marker alteration. These latter changes can be correlated with the appearance of karyotypic alterations in preneoplastic hepatocytes. On the other hand, it has been difficult to demonstrate the activation, either mutational or transcriptional, of proto-oncogenes until this stage of progression in rat hepatocarcinogenesis. Thus, a study of biochemical and molecular markers during the stages of hepatocarcinogenesis may lead to a better understanding of potential mechanisms involved in the development of neoplasia through the stages of initiation, promotion, and progression.
许多研究人员一直在寻找肝癌发生过程中发生的特定生化变化。啮齿动物肝癌发生多阶段模型的发展,重新激发了人们对癌前和肿瘤性肝细胞中此类标志物改变的兴趣。用染色剂观察时,癌前改变的肝灶(AHF)表现出特定的组织形态学变化,并通过酶、免疫组织化学和其他组织化学标志物证明存在多种生化变化。在促进的可逆阶段,当用多种标志物对AHF进行评分时,这些病变内标志物的分布因使用不同的促癌剂而有所不同。对这一发现的一种解释是,每种促癌剂都刺激一组具有特定编程表型特征的起始细胞的复制。在进展阶段,相同的标志物对AHF进行评分,但该阶段的许多AHF在表型上是异质的,在组织切片中表现出标志物改变的“灶中灶”模式。这些后期变化可能与癌前肝细胞中核型改变的出现有关。另一方面,在大鼠肝癌发生的这个进展阶段之前,很难证明原癌基因的激活,无论是突变激活还是转录激活。因此,对肝癌发生各阶段生化和分子标志物的研究,可能有助于更好地理解从起始、促进到进展阶段肿瘤形成过程中潜在的机制。